Background {#Sec1}
==========

Acute myeloid leukemia (AML), characterized by expansion of malignant myeloid precursor cells in peripheral blood and bone marrow, is the most prevalent acute leukemia in adults \[[@CR1]\]. Several AML prognostic factors have been reported, including patient age and cytogenetic features \[[@CR2], [@CR3]\]. Interestingly, Metzeler et al showed that high expression of lymphoid enhancer binding factor-1 (*LEF1*) is a favorable AML prognostic factor in non-acute promyelocytic leukemia (APL) AML \[[@CR4]\]. This study provided insights on prognostic single gene expression in AML. Therefore, we performed a systematical microarray-based analysis to search gene expression that correlates with AML overall survival (OS).

Methods {#Sec2}
=======

Microarray datasets download and analysis {#Sec3}
-----------------------------------------

We selected AML microarray datasets from Oncomine ([www.oncomine.com](http://www.oncomine.com)). Our selection criteria included (i) microarray examining adult AML patient samples; (ii) array data and patient survival data were both published; (iii) microarray data quality; and (iv) microarray used affymetrix array platform. Based on those selection criteria, we used GSE12417 and GSE8970 datasets for our analysis \[[@CR5], [@CR6]\]. GSE12417 had 2 independent cohort of samples, which were examined by affymetrix platforms GPL570 and GPL96, respectively. Specifically, GSE12417-GPL96 dataset included 163 adult AML patient gene expression profiles, while GSE12417-GPL570 dataset included 79 adult AML patient gene expression profiles. The patients were previously untreated and received cytarabine-based intensive induction and consolidation chemotherapy in the trial \[[@CR4], [@CR5]\]. GSE8970 dataset used affymetrix platform GPL96. GSE8970-GPL96 dataset included 34 adult AML patient samples. The patients were pretreated with tipifarnib \[[@CR6]\]. The stem cell transplantation status of those patients was not available. The same probe ID system was used in all above datasets, enabling results to be cross-compared. Gene expression profiles of above datasets were downloaded from NCBI Gene Expression Omnibus database. Clinic information of those patients was downloaded from Oncomine.

Our algorithm of prognostic genes identification was to identify prognostic genes in each microarray dataset and then find common prognostic genes across all tested datasets to avoid bias associated with single microarray dataset. In one dataset, single gene expression in each AML patient sample was presented by probe intensity. Patients with a probe intensity value above or below the median of all samples were categorized in probe^high^ and probe^low^ groups, respectively. Survival (1 year and 3 years) of the two groups was compared by the Mantel-Cox test, and *p* \< 0.05 was considered significant. Such calculation was repeated for all genes (probes) in the dataset by programming in R software to generate a list of prognostic genes. Common genes across both datasets were identified using the same probe ID (Fig. [1a](#Fig1){ref-type="fig"}).Fig. 1**a** Diagram showing the principal of microarray-based analysis. **b** OS according to high gene expression (gene^high^, *red*) and low gene expression (gene^low^, *blue*), analyzed using microarray datasets GSE12417 and GSE8970. GSE12417 had two independent cohorts, examined by two microarray plateforms GPL570 and GPL96. **c** OS according to *UBE2E1* ^high^ (*red*) and *UBE2E1* ^low^ (*blue*) in validation cohort. **d** Relative *UBE2E1* expression in patients with different performance status. **e** Relative *UBE2E1* expression in patients with different responses to induction chemotherapy, no response (*NR*) vs. complete response (*CR*). (\**p* \< 0.05, \*\**p* \< 0.01)

Patient samples {#Sec4}
---------------

Our validation cohort had 50 newly diagnosed AML patient samples collected at West China Hospital, Sichuan University from 2010 to 2011. The inclusive criteria include (1) adult patients (age \> 18); (2) patients with newly diagnosed AML except non-APL subtype; and (4) no chemotherapy was administered before the study. Bone marrow cell samples of the patients were collected as described previously \[[@CR7]\]. All patients were treated based on the standard protocol including anthracyclines plus cytarabine. The study was reviewed and approved by the Central Ethics Committees of Institute of Hematology/Blood Diseases Hospital, Chinese Academy of Medical Sciences, and was filed in and permitted by the Ethics Committees of West China Hospital, Sichuan University.

Quantitative RT-PCR {#Sec5}
-------------------

Total RNA was extracted from patient bone marrow cells with RNeasy Mini Kit (QIAGEN) according to the manufacturer's instruction. The expression of target genes was analyzed by qPCR using SYBR green real-time PCR system (Bio-Rad). The expression of housekeeping gene GAPDH was used as an internal control. Primers used were described in Table [1](#Tab1){ref-type="table"}.Table 1Probes for quantitative RT-PCRTarget genePrimersSequence*GAPDH*ForwardGTCTCCTCTGACTTCAACAGCGReverseACCACCCTGTTGCTGTAGCCAA*LEF1*ForwardTGCCAAATATGAATAACGACCCAReverseGAGAAAAGTGCTCGTCACTGT*FECH*ForwardGGAGATGTTCACGACTTCCTTCReverseGAATGGTGCCAGCTTATTCTGA*HBD*ForwardGAATGGTGCCAGCTTATTCTGAReverseACACCAGCCACCACCTTCTGAT*ACOT11*ForwardCATCGTGAACAATGCCTTCAAACReverseGTCCAGGACCACAAAGGTCAT*KLF1*ForwardGGTTGCGGCAAGAGCTACAReverseGTCAGAGCGCGAAAAAGCAC*FAXDC2*ForwardATTGGTGGTTGACACAACAGGReverseAGAACTGTGCGGATAGACTGG*SLC25A37*ForwardAGAAAATCATGCGGACCGAAGReverseTGGTGGTGGAAAACGTCATTTA*UBE2E1*ForwardCCTCCAAAGGTTACATTTCGGAReverseGGTCGGCAGGATTACAGTCTG

Statistical analysis {#Sec6}
--------------------

Patients' characteristics between *UBE2E1* ^high^ and *UBE2E1* ^low^ groups were analyzed using Fisher's exact test. The association between *UBE2E1* expression as well as other prognostic factors and patients' survival was investigated using univariable Cox regression and multivariable logistic regression analysis. All above statistical analyses were performed in SPSS version 22 software. Patient survival was graphed and analyzed using GraphPad Prism 5 software with Mantel-Cox test (a function of GraphPad Prism 5). A *p* \< 0.05 was considered statistically significant.

Results {#Sec7}
=======

Microarray-based analysis for AML prognostic gene expression {#Sec8}
------------------------------------------------------------

The microarray-based analysis showed that eight probes' (genes') expression was each associated with AML OS in all datasets, from 1-year survival to 3-year OS (Fig. [1b](#Fig1){ref-type="fig"}). These genes were *ACOT11*, *FAXDC2*, *FECH*, *HBD*, *KLF1*, *LEF1*, *SLC25A37*, and *UBE2E1* (Table [2](#Tab2){ref-type="table"} for chi-square and *p* value). As shown in Fig. [1b](#Fig1){ref-type="fig"}, the expression of *FAXDC2*, *FECH*, *HBD*, *KLF1*, *LEF1*, and *SLC25A37* was a favorable prognostic factor for AML, while high expression of *UBE2E1* and *ACOT11* was associated with poor OS (*p* \< 0.05). Furthermore, we compared the target genes' expression in normal BM vs. AML BM. At least in two tested microarray datasets GSE13159 and GSE1159, all target genes were aberrantly expressed in AML: AML patients had averagely increased *ACOT11* and *UBE2E1* gene expression, while the patients had lower expression of the other genes (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). In addition, we conducted multivariable analyses of the microarray datasets. The results revealed that only *UBE2E1*, *LEF1,* and *FECH1* were independent prognostic factors in AML, despite the impact of the patient age, FAB subtype as well as other prognostic factors (Table [3](#Tab3){ref-type="table"}). Interestingly, among those three identified prognostic-related single genes, high expression of *LEF1* has already been reported as a favorable prognostic factor in cytogenetically normal adult AML \[[@CR4]\].Table 2Microarray-based analysis for AML overall survival related gene expressionGSE12417-GPL570GSE12417-GPL96GSE8970-GPL961-year3-year1-year3-year1-yearGene nameProbe IDChi-square*p* valueChi-square*p* valueChi-square*p* valueChi-square*p* valueChi-square*p* value*ACOT11*214763_at6.9415230.0084211.86550.000573.885620.04874.721310.029794.037820.04449*KLF1*210504_at5.7481490.016514.251630.039214.108440.042679.618170.001935.147060.02329*LEF1*221558_s\_at14.727910.0001213.51990.000247.777760.0052911.02760.00095.147060.02329*FECH*203115_at11.521740.000699.906710.001657.005220.0081310.04920.001525.147060.02329*FAXDC2*220751_s\_at5.7869840.016157.591890.005864.012140.045177.413390.006475.147060.02329*HBD*206834_at11.873110.000577.128870.007594.426250.035396.572890.010355.147060.02329*SLC25A37*221920_s\_at5.7869840.016155.017030.02514.590610.032156.629430.010035.147060.02329*UBE2E1*212519_at4.1145440.042524.507060.033766.255730.012385.730310.016674.037820.04449 Table 3Multivariable analysis of target genes in microarray datasetsGSE8970-GPL96GSE12417-GPL96GSE12417-GPL570OSPFSOSOSHR (95% CI)*p*HR (95% CI)*p*HR (95% CI)*p*HR (95% CI)*pACOT11ACOT11* expression, high vs. low0.658(0.296,1.462)0.3040.636(0.287,1.405)0.2631.445(0.970,2.154)0.071.809(1.009,3.243)0.047Age, per 10-year increase1.201(0.704,2.048)0.5011.212(0.716,2.053)0.4741.295(1.126,1.490)\<0.0011.400(1.088,1.800)0.009Sex, male vs. female1.326(0.473,3.717)0.5921.369(0.488,3.838)0.551NANANANAPrior myelodysplastic syndrome0.685(0.270,1.741)0.4270.711(0.281,1.795)0.470NANANANAOrgan dysfunction1.162(0.490,2.753)0.7331.253(0.536,2.930)0.603NANANANAFAB subtypeNANANANA0.879(0.773,0.999)0.0480.956(0.778,1.174)0.667*FAXDC2FAXDC2* expression, high vs. low0.922(0.420.2.023)0.8391(0.462,2.166)\>0.990.869(0.590,1.280)0.4770.791(0.444,1.406)0.424Age, per 10-year increase1.185(0.685,2.051)0.5441.182(0.688,2.030)0.5451.278(1.114,1.466)\<0.0011.382(1.074,1.778)0.012Sex, male vs. female1.553(0.589,4.094)0.3731.662(0.636,4.339)0.300NANANANAPrior myelodysplastic syndrome0.681(0.265,1.753)0.4260.698(0.273,1.783)0.452NANANANAOrgan dysfunction1.094(0.471,2.539)0.8351.164(0.509,2.662)0.719NANANANAFAB subtypeNANANANA0.862(0.762,0.976)0.0190.965(0.782,1.192)0.744*FECHFECH* expression, high vs. low0.363(0.149,0.883)0.0250.390(0.163,0.934)0.0340.566(0.382,0.838)0.0050.424(0.235,0.764)0.004Age, per 10-year increase1.050(0.625,1.762)0.8541.066(0.639,1.779)0.8061.277(1.109,1.470)0.0011.410(1.095,1.817)0.008Sex, male vs. female1.932(0.734,5.089)0.1831.988(0.763,5.181)0.160NANANANAPrior myelodysplastic syndrome0.452(0.169,1.204)0.1120.486(0.184,1.284)0.146NANANANAOrgan dysfunction1.684(0.653,4.343)0.2811.781(0.697,4.554)0.228NANANANAFAB subtypeNANANANA0.855(0.757,0.967)0.0130.978(0.790,1.210)0.837*HBDHBD* expression, high vs. low0.396(0.166,0.942)0.0360.430(0.183,1.011)0.0530.528(0.356,0.783)0.0010.479(0.266,0.862)0.014Age, per 10-year increase1.015(0.594,1.732)0.9571.035(0.610,1.756)0.8981.294(1.126,1.487)\<0.0011.363(1.070,1.738)0.012Sex, male vs. female2.086(0.738,5.898)0.1662.125(0.765,5.905)0.148NANANANAPrior myelodysplastic syndrome0.595(0.221,1.605)0.3050.627(0.236,1.666)0.349NANANANAOrgan dysfunction1.479(0.595,3.681)0.4001.576(0.637,3.895)0.325NANANANAFAB subtypeNANANANA0.861(0.763,0.973)0.0160.995(0.805,1.229)0.96*KLF1KLF*1 expression, high vs. low0.457(0.208,1.000)0.0500.429(0.198,0.927)0.0310.560(0.379,0.829)0.0040.581(0.325,1.037)0.066Age, per 10-year increase1.061(0.609,1.849)0.8341.062(0.613,1.840)0.8301.281(1.111,1.476)0.0011.382(1.087,1.756)0.008Sex, male vs. female1.928(0.693,5.362)0.2092.064(0.742,5.738)0.165NANANANAPrior myelodysplastic syndrome0.562(0.204,1.547)0.2650.574(0.208,1.584)0.284NANANANAOrgan dysfunction1.184(0.492,2.845)0.7061.259(0.530,2.994)0.602NANANANAFAB subtypeNANANANA0.853(0.755,0.963)0.0110.976(0.791,1.204)0.821*LEF1LEF1* expression, high vs. low0.273(0.117,0.638)0.0030.287(0.126,0.655)0.0030.605(0.407,0.901)0.0130.382(0.209,0.700)0.002Age, per 10-year increase1.328(0.789,2.236)0.2851.342(0.802,2.245)0.2631.259(1.094,1.449)0.0011.423(1.099,1.843)0.007Sex, male vs. female2.475(0.793,7.723)0.1192.511(0.821,7.673)0.106NANANANAPrior myelodysplastic syndrome0.554(0.208,1.479)0.2390.595(0.225,1.573)0.295NANANANAOrgan dysfunction1.021(0.406,2.586)0.9661.109(0.450,2.733)0.823NANANANAFAB subtypeNANANANA0.870(0.766,0.988)0.0311.031(0.829,1.282)0.785*SLC25A37SLC25A3*7 expression, high vs. low0.312(0.117,0.827)0.0190.294(0.111,0.782)0.0140.540(0.360,0.808)0.0030.616(0.345,1.101)0.102Age, per 10-year increase0.963(0.554,1.674)0.8940.961(0.557,1.661)0.8881.292(1.122,1.488)\<0.0011.389(1.084,1.778)0.009Sex, male vs. female1.431(0.548,3.737)0.4651.474(0.568,3.828)0.425NANANANAPrior myelodysplastic syndrome0.336(0.106,1.065)0.0640.332(0.105,1.058)0.062NANANANAOrgan dysfunction1.377(0.573,3.310)0.4751.494(0.629,3.552)0.363NANANANAFAB subtypeNANANANA0.897(0.792,1.015)0.0860.983(0.796,1.214)0.872*UBE2E1UBE2E1* expression, high vs. low3.5(1.08,11.33)0.043.9(1.27,11.98)0.021.28(0.77,2.12)0.042.02(1.8,3.79)0.03Age, per 10-year increase1.04(0.96,1.13)0.321.04(0.96,1.12)0.351.02(1.00,1.04)0.031.36(1.07,1.73)0.01Sex, male vs. female1.22(0.39,3.81)0.741.51(0.52,4.42)0.45NANANANAPrior myelodysplastic syndrome0.83(0.25,2.72)0.750.88(0.29,2.71)0.83NANANANAOrgan dysfunction0.96(0.33,2.81)0.940.99(0.37,2.6)0.98NANANANAFAB subtypeNANANANA0.87(0.74,1.0)0.11.06(0.85,1.32)0.61*NA* not available

High expression of UBE2E1 is a poor prognostic factor in AML {#Sec9}
------------------------------------------------------------

We validated our findings in an independent cohort of 50 AML patients (median age 43). Target gene expression was analyzed by quantitative RT-PCR. Based on median gene expression, we divided our patients into two study groups, gene^high^ and gene^low^ groups. The survival analysis showed that out of eight genes identified by microarray studies, the expression of only one gene *UBE2E1* (ubuquitin-conjugating enzyme E2E1) was associated with AML OS in our validation cohort, and this gene was one of the three genes with independent prognostic value on multivariable analysis in the training set. The *UBE2E1* ^high^ group had a markedly shorter OS compared with *UBE2E1* ^low^ group (*p* = 0.02; Fig. [1c](#Fig1){ref-type="fig"}). Expression of the other seven genes was not associated with AML prognosis in our study (*p* \> 0.05; Additional file [1](#MOESM1){ref-type="media"}: Figure S2). We could not detect *KLF1* expression in AML patient samples, although the qPCR primers for this gene were validated.

Next, we performed multivariable analysis to verify the prognostic significance of *UBE2E1* expression in our validation cohort. The patient characteristics of *UBE2E1* ^high^ and *UBE2E1* ^low^ groups are shown in Table [4](#Tab4){ref-type="table"}. No significant difference in patient characteristics, such as age, FAB subtypes, WBC count, BM blast percentages, gene mutations, was found between the two groups. We found no difference in patients' treatment between those two groups (Table [5](#Tab5){ref-type="table"}). *UBE2E1* ^high^ patients had a short OS (*p* = 0.04) as well as a short progression-free survival (*p* = 0.03) compared with *UBE2E1* ^low^ patients after adjusting for the impact of other prognostic factors including patient age, gender, performance status, and response to induction chemotherapy (Table [6](#Tab6){ref-type="table"}).Table 4Characteristic of AML patients in validation cohortVariable*UBE2E1* ^high^ *n* = 25*UBE2E1* ^low^ *n* = 25*p* valueMedian age43.0843.250.567Female, no. (%)10(40)13(52)0.395Secondary or treatment-related AML, no. (%)2(8)2(8)\>0.99FAB subtype , no.0.838 M~1~33 M~2~1012 M~4~75 M~5~13 M~6~20 NA22Median WBC, 10^9^/L (range)6.83(0.3--244.38)23.88(0.68--366)0.289Median BM plasts, %, (range)49.5(11--94)65.5(22--90.5)0.175Median platelet count, 10^9^/L (range)39(4--151)35.5(4--180)0.918*CEBPA* mutated, no. (%)2(8)5(20)0.179Missing date13*NPM1* mutated, no. (%)2(8)4(16)0.327Missing date13*IDH1* mutated, no. (%)00\>0.99Missing date13*FLT3*-*TKD* mutated, no. (%)01(4)0.296Missing date13*FLT3*-*ITD* mutated, no. (%)02(4)0.149Missing date13*AML1*/*ETO* mutated, no. (%)4(16)6(24)0.389Missing date13*C-KIT* D816V mutated, no. (%)1(4)2(8)0.504Missing date13*CBEB*-*MYH11* mutated, no. (%)2(8)3(12)0.568Missing date13 Table 5Characteristic of AML patients treatment in validation cohortVariable*UBE2E1* ^high^*UBE2E1* ^low^*p*Treatment, no.(%)25(100)25(100)0.422CAG2(8)1(4)DA9(36)11(44)QA1(4)0HAD1(4)0IDA6(24)11(44)D-CAG2(8)1(4)Allo-HSCT0(0)0(0) Table 6Multivariable analysis in validation cohortOSPFSHR (95% CI)*p*HR (95% CI)*pUBE2E1* expression, high vs. low3.227(1.05,9.852)0.0403.818(1.616,12.553)0.027Age, per 10-year increase1.666(1.112,2.498)0.0131.536(1.02,2.313)0.040Sex, male vs. female0.628(0.214,1.84)0.3960.559(0.183,1.71)0.308Performance status0.727(0.374,1.41)0.3450.683(0.344,1.358)0.277Induction chemo-response1.472(0.845,2.566)0.1721.51(0.853,2.672)0.157

UBE2E1 expression and its association with chemotherapy response {#Sec10}
----------------------------------------------------------------

Finally, in our validation cohort, low *UBE2E1* expression was associated with a better performance status in the patients (Fig. [1d](#Fig1){ref-type="fig"}; *p* \< 0.05). We also found that *UBE2E1* expression was associated with response to induction chemotherapy. Patients who had relatively higher *UBE2E1* expression were more likely to achieve no response (NR) to chemotherapy while patients who had lower *UBE2E1* expression were more likely to enter complete remission (CR) (Fig. [1e](#Fig1){ref-type="fig"}; *p* \< 0.05). This result suggests that *UBE2E1* expression may be a possible predictor for chemotherapy response in AML patients.

Discussion {#Sec11}
==========

In this study, we performed a genome-wide screening to identify gene expression that correlate with adult AML OS. The gene expression profiles (GEPs) from 2 independent datasets of patient samples were used in our analysis. The correlation of each gene expression and AML OS was calculated by a program coded by R software. Only gene identified with statistical significance in both datasets was considered as positive results for further test. By this strategy of analysis, we identified 8 AML prognostic genes. Next, we tested our findings using an independent cohort of 50 AML samples. Our result suggested that although several genes, such as *HBD* and *ACOT11*, had trend correlation, only one gene, *UBE2E1*, was statistically correlated with AML OS in our validation cohort. The negative findings of other 7 genes in our validation cohort might be caused by the relatively small number of patients. In addition, we noticed that the patients in microarray-testing cohort and our validation cohort had different ethnic backgrounds. Further studies might be necessary to draw a more confirmative conclusion.

Mounting evidence has shown that AML is highly heterogeneous and dynamic \[[@CR8]\]. The heterogeneous entity of AML emerges from the disease genetic basis, leukemogenesis, pathophysiology, and prognosis. However, cluster of gene expression signature \[[@CR5]\], or even single gene expression \[[@CR4]\], has been shown to correlate with AML prognosis. Therefore, what is the interpretation of prognostic single gene expression, such as *UBE2E1* and *LEF1*, in AML? We hypothesized that different subgroups of AML, with discrete driver mutations, might have similar epigenetic effectors' upregulation/downregulation, which correlate with patient's survival. We also hypothesized that in different prognosis-relevant AML subgroups, the effectors have patterned expression. To test these hypotheses, we performed another microarray-based analysis for *UBE2E1* expression in AML with complex karyotype vs. normal karyotype, *FLT3* mutation vs. wildtype*FLT3*, and *NPM1* mutation vs. wildtype*NPM1*. We selected those genetic abnormalities because they have high frequency of occurrence in AML and correlate with the patient clinical outcome: patients with complex karyotype or *FLT3* mutation had poor treatment outcome, while patients with *NPM1* mutation had good treatment outcome \[[@CR8]\]. As shown in Additional file [1](#MOESM1){ref-type="media"}: Table S1, complex karyotype or *FLT3*-mutated AML had relatively high *UBE2E1* expression, compared with normal karyotype or wildtype *FLT3* AML, respectively. *NPM1*-mutated AML had relatively low *UBE2E1* expression. These preliminary findings might indicate that *UBE2E1* have patterned expressions, which was well matched with AML classification despite of different genetic basis.

Protein ubiquitination was accomplished by sequential action of enzymes E1, E2, and E3. Specifically, E2 transferred E1-activated ubiquitin to E3, an ubiquitin ligase, and formed an isopeptide bond between ubiquitin and protein substrate. *UBE2E1* was a member of ubiquitin-conjugating enzyme E2 class. Zhu et al. showed that *UBE2E1* regulated *HOX* gene expression by ubiquitinating histones \[[@CR9]\]. Thus, *UBE2E1* might play a regulatory role in cell by selectively ubiquitinating target proteins. The function of *UBE2E1* in cell signaling is still largely unknown. However, the regulation of *UBE2E1* on *HOX* gene might be a key to understand the prognostic role of *UBE2E1* in AML. *HOX* gene is a family of highly conserved homeodomain transcription factor genes \[[@CR10]\]. There are 39 *HOX* genes, belonging to 4 gene clusters, in human. Previous work has shown that *HOX* genes are aberrantly expressed in AML \[[@CR11], [@CR12]\]. Animal study indicated that overexpression *HOX* gene, *HOXA10* and *HOXA9*, promoted AML leukemogenesis \[[@CR13], [@CR14]\]. To identify potential *UBE2E1* downstream *HOX* genes, we started with microarray datasets. We found co-expression of *UBE2E1* with *HOXA11* in AML. We also examined *HOXA11* and *UBE2E1* co-expression in our validation cohort (Additional file [1](#MOESM1){ref-type="media"}: Figure S3). Interestingly, a recent publication suggested that *HOXA11* expression correlated with glioblastoma patient treatment responses and prognosis \[[@CR15]\]. Thus, it is highly possible that *UBE2E1* regulates AML chemoresistance through *HOXA11*.

In our study, we found co-expression of *UBE2E1* with *HOX* family gene, *HOXA11*, in AML. Therefore, we hypothesized that *UBE2E1* regulates *HOXA11* gene expression in AML, and *HOXA11* transcription factor level might be relevant to AML treatment resistance. We are actively conducting more mechanistic studies to demonstrate the role of *UBE2E1* in AML.

Conclusions {#Sec12}
===========

In conclusion, we performed a genome-wide, microarray-based analysis for gene expressions that correlated with AML survival, and found 8 candidate genes. We further tested these genes in an independent validation cohort of 50 AML samples, and identified that *UBE2E1* expression adversely correlated with AML prognosis.

Additional file {#Sec13}
===============

Additional file 1: Figure S1.Aberrant target gene expression in AML. AML patient samples microarray datasets GSE13159 and GSE1159 were downloaded from NCBI. Normal samples in those datasets were bone marrow cells or peripheral blood mononuclear cells (PBMCs) from healthy donors. Target gene expression in normal samples vs. AML patient samples were plotted and compared by the Student's *t* test (\*\**p* \< 0.01). **Figure S2.** Target gene correlation with patient survival in validation cohort. **Figure S3.** Co-expression of UBE2E1 and HOXA11 in AML. **Table S1.** UBE2E1 expression in AML subgroups. (PPTX 202 kb)
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